Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMD3100 for Stem Cell Mobilization in Lymphoma and Myeloma
NCT00665314Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and multiple myeloma (MM) comparing AMD3100 + G-CSF with Placebo + G-CSF (2 arms). Primary endpoint: Proportion of patients reaching target of >= 2x10^6 CD34+ cells/kg within 2 days of apheresis. Started Nov 2007; status: completed.
02
Drugs
plerixafor
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00665314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00665314.